TCP
ACAD icon

Tourbillon Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Tourbillon Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-400,000
Closed -$13M – 100
2015
Q1 		$13M Buy
+400,000
New +$13.7M 0.34% 57
2014
Q2 		– Sell
-350,000
Closed -$8.52M – 67
2014
Q1 		$8.52M Buy
+350,000
New +$8.85M 0.4% 57

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Tourbillon Capital Partners's ACAD Position: Q2 2015 in Review

Tourbillon Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2015, closing a stake of 400,000 shares — an estimated $13M sold.

Tourbillon Capital Partners first reported a position in ACAD in Q1 2014 and held it in 2 quarters. The position peaked at $13M in Q1 2015. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

  • Tourbillon Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 400,000 Acadia Pharmaceuticals shares in Q2 2015, an estimated $13M.
  • Tourbillon Capital Partners first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Tourbillon Capital Partners's Acadia Pharmaceuticals position peaked at $13M in Q1 2015.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on Tourbillon Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.